Plain-English translation of NCT07048314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether HB-adMSCs (stem cells grown from fat tissue donated by healthy volunteers) can help restore the ability to have erections in men who have had prostate cancer surgery. Erectile dysfunction is a common side effect of this surgery because the procedure can damage nerves and blood vessels in the penis. The medication is injected directly into the penis and/or delivered through the bloodstream to see if it can help repair this damage and restore sexual function.
Many men who have surgery to remove a cancerous prostate lose the ability to have erections, even when nerve-sparing surgical techniques are used. Current treatments like pills and injections don't work for everyone. This trial is exploring whether this medication can actually repair the damaged tissue and restore natural function rather than just masking the problem.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of four groups that receive different combinations of the medication and placebo (salt water). You will receive one injection during your prostate removal surgery and another injection or infusion 12 weeks later at a clinic visit. The study lasts 24 weeks total, and you'll have follow-up appointments to check your erectile function using questionnaires and medical exams. You won't know which group you're in—this is a "blinded" study where neither you nor your doctors initially know whether you're receiving the active treatment or placebo.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States